A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer. A phase 3 trial analyzing the treatment combination ...

Merck (NYSE:MRK) is discontinuing a phase 3 trial of a Keytruda combination treatment for prostate cancer after the study failed its main goals, while another late stage trial of the blockbuster drug ...

A combination of chemotherapy and immunotherapy has proven promising in treating patients with advanced Hodgkin Lymphoma, and removes the need for radiation therapy in kids. In a new phase 3 clinical ...

Merck (NYSE:MRK) said it will stop a phase 3 trial of a Keytruda combo therapy to treat a type of prostate cancer after the treatment failed to improve survival. Merck said it is discontinuing the ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

Urinary tract infections (UTIs) are common and treatable, but there can be complications, especially when the bacteria become drug resistant. Now, a new drug combo has shown promise in a Phase 3 ...

Moderna's combo flu and COVID vaccine provided a strong immune response in older adults, with levels comparable to getting the flu and COVID shots separately, according to the company's results from a ...

A trial evaluating the combination therapy of a drug and an antioxidant shows promise in treating Alzheimer’s disease, according to a new report. The study was published Thursday in Nature Medicine.

A new clinical trial studying the effectiveness of a combination of immunotherapy treatments could be more effective for patients with ovarian cancer who are resistant to traditional interventions.